Barclays’s bluebird bio BLUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-116
| Closed | -$132K | – | 6143 |
|
|
2019
Q4 | $132K | Sell |
116
-77
| -40% | -$83.7K | ﹤0.01% | 5314 |
|
|
2019
Q3 | $230K | Buy |
193
+77
| +66% | +$118K | ﹤0.01% | 4864 |
|
|
2019
Q2 | $191K | Hold |
116
| – | – | ﹤0.01% | 5153 |
|
|
2019
Q1 | $236K | Sell |
116
-69
| -37% | -$122K | ﹤0.01% | 4700 |
|
|
2018
Q4 | $238K | Hold |
185
| – | – | ﹤0.01% | 4458 |
|
|
2018
Q3 | $350K | Sell |
185
-942
| -84% | -$1.95M | ﹤0.01% | 4563 |
|
|
2018
Q2 | $2.29M | Sell |
1,127
-5,111
| -82% | -$11.6M | ﹤0.01% | 2454 |
|
|
2018
Q1 | $13.8M | Buy |
6,238
+6,114
| +4,931% | +$15.6M | 0.01% | 1027 |
|
|
2017
Q4 | $285K | Sell |
124
-30
| -19% | -$60.9K | ﹤0.01% | 4387 |
|
|
2017
Q3 | $275K | Buy |
154
+7
| +5% | +$9.78K | ﹤0.01% | 4153 |
|
|
2017
Q2 | $200K | Buy |
+147
| New | +$177K | ﹤0.01% | 4353 |
|
Barclays's BLUE Position: Q3 2025 in Review
Barclays sold out of bluebird bio (BLUE) in Q3 2025, closing a stake of 1 share — an estimated $4 sold.
Barclays first reported a position in BLUE in Q3 2013 and held it in 48 quarters. The position peaked at $18.1M in Q1 2018. 0 funds tracked by Wall St. Rank hold BLUE as of Q3 2025.
- Barclays reported no remaining bluebird bio position as of Q3 2025 after selling out during the quarter.
- Barclays sold 1 bluebird bio share in Q3 2025, an estimated $4.
- Barclays first reported a position in bluebird bio in Q3 2013 and held it in 48 quarters.
- Barclays's bluebird bio position peaked at $18.1M in Q1 2018.
- 0 funds tracked by Wall St. Rank held bluebird bio as of Q3 2025.
Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.